SIMULATIONS PLUS INC

Insider selling trend at Simulations Plus: Chief Revenue Officer DiBella’s recent 1,000‑share sale hints at a cautious portfolio shift amid rising drug‑simulation prospects.

Insider sale by Walter Woltosz reveals disciplined 10b‑5‑1 trading but hints at rising valuation for Simulations Plus, a fast‑growing health‑tech stock.

Insider buys low, sells high: Jill Fiedler‑Kelly’s Simulations Plus trades signal confidence in Altaris’s $375 m cash deal and a strategic 26 % premium.

Jill Fiedler‑Kelly’s insider buy‑sell cycle at Simulations Plus signals cautious optimism as the company seeks to monetize its drug‑simulation platform.

DiBella’s 1,000‑share sale shows routine liquidity, not lost confidence, as Simulations Plus insiders continue buying options amid rising drug‑simulation demand.

Insider buying signals at Simulations Plus Inc. reveal growing confidence as executives purchase shares at zero cost, hinting at potential upside.

Evans Sharlene’s insider buy of 1,776 shares at $0 shows confidence in Simulations Plus, hinting at future upside amid a volatile price decline.